High Power Short Duration Ablation for Atrial Fibrillation
Pulmonary Vein Isolation Strategy of Very High Power Short Duration in Patients With Paroxysmal Atrial Fibrillation: Q-INDEX Trial
This study is testing a new quick and powerful heart procedure to see if it can better help people with paroxysmal atrial fibrillation compared to standard methods.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 150 (estimated) |
| Ages | 19 Years and up |
| Sex | All |
| Sponsor | Seoul National University Hospital Academic / other |
| Locations | 1 site (Seoul) |
| Trial ID | NCT05996159 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of a novel ablation technique using very high power and short duration to treat patients with paroxysmal atrial fibrillation. The approach employs the QDOT Micro catheter and AI-guided ablation to enhance procedural efficiency and effectiveness. By reducing the ablation time while maintaining safety and efficacy, the study aims to improve patient outcomes in rhythm control. The research will compare this method to conventional ablation techniques to assess its viability and success rates.
Who should consider this trial
Good fit: Ideal candidates for this study are patients undergoing pulmonary vein isolation for paroxysmal atrial fibrillation.
Not a fit: Patients with persistent atrial fibrillation or those who have had previous ablation or surgery for atrial fibrillation may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to shorter procedure times and improved outcomes for patients with paroxysmal atrial fibrillation.
How similar studies have performed: Other studies have shown promising results with similar high-power ablation techniques, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients undergoing PVI for PAF Exclusion Criteria: * Aged less than 19 years * Patients with persistent AF * Patients with previous ablation or surgery for AF * Patients with intracardiac thrombus or thromboembolic events within the previous 90 days * Patients with cardiac surgery or acute coronary syndrome within the previous 90 days * Patients with contraindication(s) for using oral anticoagulants * Patients with LA anteroposterior diameter of more than 55 mm * Patients with left ventricular ejection fraction less than 35% * Pregnants or those who plan to become pregnant during the study * Life expectancy less than a year
Where this trial is running
Seoul
- Seoul National University Hospital — Seoul, South Korea (Recruiting)
Study contacts
- Principal investigator: Eue-Keun Choi, M.D. Ph.D. — Seoul National University Hospital
- Study coordinator: Eue-Keun Choi, M.D. Ph.D.
- Email: choiek417@gmail.com
- Phone: 82-2-2072-0688
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.